Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment

Conclusion Skin AEs are common in patients with MS treated with cladribine. Until risk management plans have been adjusted to include these phenomena, clinicians should perform a thorough clinical follow-up and in suspicious cases seek early interdisciplinary support. In light of the observed delayed skin reactions, we further emphasize the necessity of careful clinical surveillance of cladribine-treated patients for yet undescribed secondary autoimmune events. Classification of Evidence This study provides Class IV evidence that skin-related AEs are frequent in patients with MS following cladribine in a real-world setting.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Autoimmune diseases, Class IV, Multiple sclerosis Article Source Type: research